Cue Biopharma Inc (CUE)
1.05
+0.02
(+1.94%)
USD |
NASDAQ |
Nov 22, 16:00
1.05
0.00 (0.00%)
After-Hours: 16:32
Cue Biopharma Enterprise Value: 38.12M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 38.12M |
| November 20, 2024 | 41.92M |
| November 19, 2024 | 41.29M |
| November 18, 2024 | 42.56M |
| November 15, 2024 | 51.74M |
| November 14, 2024 | 67.90M |
| November 13, 2024 | 67.90M |
| November 12, 2024 | 80.57M |
| November 11, 2024 | 85.46M |
| November 08, 2024 | 76.43M |
| November 07, 2024 | 80.04M |
| November 06, 2024 | 72.21M |
| November 05, 2024 | 75.83M |
| November 04, 2024 | 62.58M |
| November 01, 2024 | 64.39M |
| October 31, 2024 | 69.81M |
| October 30, 2024 | 78.23M |
| October 29, 2024 | 74.62M |
| October 28, 2024 | 80.04M |
| October 25, 2024 | 61.98M |
| October 24, 2024 | 66.80M |
| October 23, 2024 | 67.40M |
| October 22, 2024 | 69.20M |
| October 21, 2024 | 74.02M |
| October 18, 2024 | 45.72M |
| Date | Value |
|---|---|
| October 17, 2024 | 39.70M |
| October 16, 2024 | 37.29M |
| October 15, 2024 | 40.30M |
| October 14, 2024 | 45.72M |
| October 11, 2024 | 46.93M |
| October 10, 2024 | 52.95M |
| October 09, 2024 | 45.42M |
| October 08, 2024 | 46.93M |
| October 07, 2024 | 56.26M |
| October 04, 2024 | 42.71M |
| October 03, 2024 | 22.19M |
| October 02, 2024 | 17.03M |
| October 01, 2024 | 16.20M |
| September 30, 2024 | 18.46M |
| September 27, 2024 | 9.268M |
| September 26, 2024 | -1.691M |
| September 25, 2024 | -0.6696M |
| September 24, 2024 | -0.2026M |
| September 23, 2024 | -0.4701M |
| September 20, 2024 | 1.709M |
| September 19, 2024 | 3.704M |
| September 18, 2024 | 3.154M |
| September 17, 2024 | 3.947M |
| September 16, 2024 | 3.626M |
| September 13, 2024 | 4.871M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-1.691M
Minimum
Sep 26 2024
825.53M
Maximum
Jun 02 2020
203.11M
Average
115.26M
Median
Jun 05 2023
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 11.76B |
| Arbutus Biopharma Corp | 527.85M |
| GlycoMimetics Inc | 6.243M |
| FibroGen Inc | 22.76M |
| Cidara Therapeutics Inc | -4.423M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.66M |
| Revenue (Quarterly) | 3.336M |
| Total Expenses (Quarterly) | 12.25M |
| EPS Diluted (Quarterly) | -0.17 |
| Profit Margin (Quarterly) | -259.6% |
| Earnings Yield | -86.67% |
| Normalized Earnings Yield | -86.53 |